Skip to main content

Advertisement

Log in

Proteasome inhibitor, bortezomib, for myeloma and lymphoma

  • REVIEW ARTICLE
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Bortezomib, a boronic acid, is a potent and selective proteasome inhibitor. The 20S proteasome is an enzyme complex present in cells, and it degrades many cell-cycle control factors, signal transduction factors, transcription factors, and oncogene and anti-oncogene products, thus controlling cell proliferation, differentiation, and apoptosis. Bortezomib is a novel molecular targeting agent which was designed to exhibit an antitumor effect by selectively inhibiting the 20S proteasome. Multiple myeloma is one of the incurable B-cell malignancies that continues to relapse with current treatment modalities, and the duration to progression becomes shorter in patients who repeatedly receive chemotherapy. There are no available treatment options in which durable efficacy can be expected after relapse; therefore, an effective therapy with a novel mechanism of action has been desired. In this review article, the results of clinical trials of bortezomib for multiple myeloma, including a Japanese phase I/II and pharmacokinetic/pharmacodynamic study, and those for non-Hodgkin lymphoma, especially for mantle cell lymphoma, are summarized. In the Japanese phase I/II study of bortezomib for relapsed multiple myeloma, this agent showed remarkable efficacy, with acceptable toxicities and unique pharmacokinetic/pharmacodynamic profiles, warranting further investigations, including more relevant administration schedules.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. AF Kisselev AL Goldberg (2001) ArticleTitleProteasome inhibitors: from research tools to drug candidates Chem Biol 8 739–758 Occurrence Handle11514224 Occurrence Handle10.1016/S1074-5521(01)00056-4 Occurrence Handle1:CAS:528:DC%2BD3MXmtV2ku7g%3D

    Article  PubMed  CAS  Google Scholar 

  2. CG Maki JM Huibregtse PM Howley (1996) ArticleTitleIn vivo ubiquitination and proteasome-mediated degradation of p53 Cancer Res 56 2649–2654 Occurrence Handle8653711 Occurrence Handle1:CAS:528:DyaK28XjtlCgu70%3D

    PubMed  CAS  Google Scholar 

  3. BE Clurman RJ Sheaff K Thress et al. (1996) ArticleTitleTurnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation Genes Dev 10 1979–1990 Occurrence Handle8769642 Occurrence Handle10.1101/gad.10.16.1979 Occurrence Handle1:CAS:528:DyaK28XlsVaqt74%3D

    Article  PubMed  CAS  Google Scholar 

  4. H Tatebe M Yanagida (2000) ArticleTitleCut8, essential for anaphase, controls localization of 26S proteasome, facilitating destruction of cyclin and Cut2 Curr Biol 10 1329–1338 Occurrence Handle11084332 Occurrence Handle10.1016/S0960-9822(00)00773-9 Occurrence Handle1:CAS:528:DC%2BD3cXotVOhtrw%3D

    Article  PubMed  CAS  Google Scholar 

  5. C Cayrol B Ducommun (1998) ArticleTitleInteraction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21 Oncogene 17 2437–2444 Occurrence Handle9824154 Occurrence Handle10.1038/sj.onc.1202189 Occurrence Handle1:CAS:528:DyaK1cXnvVehsrs%3D

    Article  PubMed  CAS  Google Scholar 

  6. M Pagano SW Tam AM Theodoras et al. (1995) ArticleTitleRole of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 Science 269 682–685 Occurrence Handle7624798 Occurrence Handle10.1126/science.7624798 Occurrence Handle1:CAS:528:DyaK2MXntlCltrc%3D

    Article  PubMed  CAS  Google Scholar 

  7. J Adams VJ Palombella EA Sausville et al. (1999) ArticleTitleProteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res 59 2615–2622 Occurrence Handle10363983 Occurrence Handle1:CAS:528:DyaK1MXjs1ymsbY%3D

    PubMed  CAS  Google Scholar 

  8. J Adams VJ Palombella PJ Elliott (2000) ArticleTitleProteasome inhibition: a new strategy in cancer treatment Invest New Drugs 18 109–121 Occurrence Handle10857991 Occurrence Handle10.1023/A:1006321828515 Occurrence Handle1:CAS:528:DC%2BD3cXkt1CntLc%3D

    Article  PubMed  CAS  Google Scholar 

  9. T Hideshima D Chauhan R Schlossman et al. (2001) ArticleTitleThe role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications Oncogene 20 4519–4527 Occurrence Handle11494147 Occurrence Handle10.1038/sj.onc.1204623 Occurrence Handle1:CAS:528:DC%2BD3MXlvVGktr4%3D

    Article  PubMed  CAS  Google Scholar 

  10. T Hideshima P Richardson D Chauhan et al. (2001) ArticleTitleThe proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res 61 3071–3076 Occurrence Handle11306489 Occurrence Handle1:CAS:528:DC%2BD3MXivFGqsL0%3D

    PubMed  CAS  Google Scholar 

  11. N Mitsiades CS Mitsiades V Poulaki et al. (2002) ArticleTitleMolecular sequelae of proteasome inhibition in human multiple myeloma cells Proc Natl Acad Sci USA 99 14 374–14 379 Occurrence Handle10.1073/pnas.202445099 Occurrence Handle1:CAS:528:DC%2BD38XosF2iu7Y%3D

    Article  CAS  Google Scholar 

  12. T Hideshima C Mitsiades M Akiyama et al. (2003) ArticleTitleMolecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 Blood 101 1530–1534 Occurrence Handle12393500 Occurrence Handle10.1182/blood-2002-08-2543 Occurrence Handle1:CAS:528:DC%2BD3sXht1ansr4%3D

    Article  PubMed  CAS  Google Scholar 

  13. MM Oken (1994) ArticleTitleStandard treatment of multiple myeloma Mayo Clin Proc 69 781–786 Occurrence Handle8035637 Occurrence Handle1:STN:280:DyaK2czgvFegsw%3D%3D

    PubMed  CAS  Google Scholar 

  14. MM Oken (1998) ArticleTitleManagement of myeloma: current and future approaches Cancer Control 5 218–225 Occurrence Handle10761055

    PubMed  Google Scholar 

  15. InstitutionalAuthorNameMyeloma Trialists Collaborative Group (1998) ArticleTitleCombination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials J Clin Oncol 16 3832–3842

    Google Scholar 

  16. T Takenaka K Itoh T Suzuki et al. (2004) ArticleTitlePhase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan Clinical Oncology Group study, JCOG 9301 Int J Hematol 79 165–173 Occurrence Handle15005346 Occurrence Handle1:CAS:528:DC%2BD2cXitlymtrY%3D

    PubMed  CAS  Google Scholar 

  17. B Barlogie L Smith R Alexanian (1984) ArticleTitleEffective treatment of advanced multiple myeloma refractory to alkylating agents N Engl J Med 310 1353–1356 Occurrence Handle6546971 Occurrence Handle1:STN:280:DyaL2c7ptFemtg%3D%3D Occurrence Handle10.1056/NEJM198405243102104

    Article  PubMed  CAS  Google Scholar 

  18. M Attal JL Harousseau T Facon et al. (2003) ArticleTitleSingle versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 349 2495–2502 Occurrence Handle14695409 Occurrence Handle10.1056/NEJMoa032290 Occurrence Handle1:CAS:528:DC%2BD3sXhtVWit7vF

    Article  PubMed  CAS  Google Scholar 

  19. M Attal J Harousseau J Stoppa et al. (1996) ArticleTitleA prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma N Engl J Med 335 91–97 Occurrence Handle8649495 Occurrence Handle10.1056/NEJM199607113350204 Occurrence Handle1:STN:280:DyaK283ms1emuw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  20. JA Child GJ Morgan FE Davies et al. (2003) ArticleTitleHigh-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 1875–1883 Occurrence Handle12736280 Occurrence Handle10.1056/NEJMoa022340 Occurrence Handle1:CAS:528:DC%2BD3sXjsVChtLo%3D

    Article  PubMed  CAS  Google Scholar 

  21. B Barlogie RA Kyle KC Anderson et al. (2006) ArticleTitleStandard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 J Clin Oncol 24 929–936 Occurrence Handle16432076 Occurrence Handle10.1200/JCO.2005.04.5807 Occurrence Handle1:CAS:528:DC%2BD28Xitl2qt7w%3D

    Article  PubMed  CAS  Google Scholar 

  22. AC Buzaid BG Durie (1988) ArticleTitleManagement of refractory myeloma: a review J Clin Oncol 6 889–905 Occurrence Handle2452861 Occurrence Handle1:STN:280:DyaL1c3hsVCmug%3D%3D

    PubMed  CAS  Google Scholar 

  23. A Paccagnella V Chiarion-Sileni M Soesan et al. (1991) ArticleTitleSecond and third responses to the same induction regimen in relapsing patients with multiple myeloma Cancer 68 975–980 Occurrence Handle1913491 Occurrence Handle10.1002/1097-0142(19910901)68:5<975::AID-CNCR2820680511>3.0.CO;2-O Occurrence Handle1:STN:280:DyaK38%2FgsFahug%3D%3D

    Article  PubMed  CAS  Google Scholar 

  24. Stewart KA, O'Connor OA, Alsina M, et al. (2007) Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses. Proc Am Soc Clin Oncol 25: no. 8003

    Google Scholar 

  25. RZ Orlowski TE Stinchcombe BS Mitchell et al. (2002) ArticleTitlePhase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J Clin Oncol 20 4420–4427 Occurrence Handle12431963 Occurrence Handle10.1200/JCO.2002.01.133 Occurrence Handle1:CAS:528:DC%2BD38XosFCjs70%3D

    Article  PubMed  CAS  Google Scholar 

  26. C Aghajanian S Soignet DS Dizon et al. (2002) ArticleTitleA phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies Clin Cancer Res 8 2505–2511 Occurrence Handle12171876 Occurrence Handle1:CAS:528:DC%2BD38XmvVaiu7g%3D

    PubMed  CAS  Google Scholar 

  27. PG Richardson B Barlogie J Berenson et al. (2003) ArticleTitleA phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609–2617 Occurrence Handle12826635 Occurrence Handle10.1056/NEJMoa030288 Occurrence Handle1:CAS:528:DC%2BD3sXkvVSksLs%3D

    Article  PubMed  CAS  Google Scholar 

  28. S Jagannath B Barlogie J Berenson et al. (2004) ArticleTitleA phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 127 165–172 Occurrence Handle15461622 Occurrence Handle10.1111/j.1365-2141.2004.05188.x Occurrence Handle1:CAS:528:DC%2BD2cXpvFait7g%3D

    Article  PubMed  CAS  Google Scholar 

  29. J Blade D Samson D Reece et al. (1998) ArticleTitleCriteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation Br J Haematol 102 1115–1123 Occurrence Handle9753033 Occurrence Handle10.1046/j.1365-2141.1998.00930.x Occurrence Handle1:STN:280:DyaK1cvitl2mtw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  30. PG Richardson B Barlogie J Berenson et al. (2005) ArticleTitleClinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma Blood 106 2977–2981 Occurrence Handle16020506 Occurrence Handle10.1182/blood-2005-02-0691 Occurrence Handle1:CAS:528:DC%2BD2MXht1Wntr%2FM

    Article  PubMed  CAS  Google Scholar 

  31. S Jagannath B Barlogie JR Berenson et al. (2005) ArticleTitleBortezomib in recurrent and/or refractory multiple myeloma: initial clinical experience in patients with impaired renal function Cancer 103 1195–1200 Occurrence Handle15690325 Occurrence Handle10.1002/cncr.20888 Occurrence Handle1:CAS:528:DC%2BD2MXivFWgsL0%3D

    Article  PubMed  CAS  Google Scholar 

  32. S Lonial EK Waller PG Richardson et al. (2005) ArticleTitleRisk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma Blood 106 3777–3784 Occurrence Handle16099887 Occurrence Handle10.1182/blood-2005-03-1173 Occurrence Handle1:CAS:528:DC%2BD2MXht12ksbnF

    Article  PubMed  CAS  Google Scholar 

  33. P Richardson P Sonneveld MW Schuster et al. (2005) ArticleTitleBortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2487–2498 Occurrence Handle15958804 Occurrence Handle10.1056/NEJMoa043445 Occurrence Handle1:CAS:528:DC%2BD2MXltlaksLc%3D

    Article  PubMed  CAS  Google Scholar 

  34. Richardson PG, Sonneveld P, Schuster M, et al. (2005) Bortezomib continues demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial. Blood (ASH Annual Meeting Abstracts) 106: no. 2547

  35. RC Kane AT Farrell R Sridhara et al. (2006) ArticleTitleUnited States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy Clin Cancer Res 12 2955–6290 Occurrence Handle16707588 Occurrence Handle10.1158/1078-0432.CCR-06-0170 Occurrence Handle1:CAS:528:DC%2BD28Xks1Cisb8%3D

    Article  PubMed  CAS  Google Scholar 

  36. PG Richardson P Sonneveld MW Schuster et al. (2007) ArticleTitleSafety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma Br J Haematol 137 429–435 Occurrence Handle17451408 Occurrence Handle10.1111/j.1365-2141.2007.06585.x Occurrence Handle1:CAS:528:DC%2BD2sXotVOgsrk%3D

    Article  PubMed  CAS  Google Scholar 

  37. PR Greipp J San Miguel BG Durie et al. (2005) ArticleTitleInternational staging system for multiple myeloma J Clin Oncol 23 3412–3420 Occurrence Handle15809451 Occurrence Handle10.1200/JCO.2005.04.242

    Article  PubMed  Google Scholar 

  38. S Jagannath BG Durie J Wolf et al. (2005) ArticleTitleBortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma Br J Haematol 129 776–783 Occurrence Handle15953004 Occurrence Handle10.1111/j.1365-2141.2005.05540.x Occurrence Handle1:CAS:528:DC%2BD2MXms1ehsLw%3D

    Article  PubMed  CAS  Google Scholar 

  39. Harousseau JL, Nagler A, Sonneveld P, et al. (2007) Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone. Proc Am Soc Clin Oncol 25: no. 8002

    Google Scholar 

  40. RZ Orlowski PM Voorhees RA Garcia et al. (2005) ArticleTitlePhase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Blood 105 3058–3065 Occurrence Handle15626743 Occurrence Handle10.1182/blood-2004-07-2911 Occurrence Handle1:CAS:528:DC%2BD2MXjtlSmtbo%3D

    Article  PubMed  CAS  Google Scholar 

  41. Tobinai K, Watanabe T, Ogawa Y, et al. (2006) Pharmacokinetic (PK) and pharmacodynamic (PD) profiles of bortezomib (B) in patients (pts) with relapsed multiple myeloma (MM): a phase I/II study in Japan. Blood (ASH Annual Meeting Abstracts) 108: no. 5106

  42. S Miyakoshi M Kami K Yuji et al. (2006) ArticleTitleSevere pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma Blood 107 3492–3494 Occurrence Handle16410442 Occurrence Handle10.1182/blood-2005-11-4541 Occurrence Handle1:CAS:528:DC%2BD28Xkt1GitLo%3D

    Article  PubMed  CAS  Google Scholar 

  43. A Gotoh K Ohyashiki K Oshimi et al. (2006) ArticleTitleLung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the “Lung Injury by Bortezomib” joint committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology Int J Hematol 84 406–412 Occurrence Handle17189220 Occurrence Handle10.1532/IJH97.06142 Occurrence Handle1:CAS:528:DC%2BD2sXhsVSmsr8%3D

    Article  PubMed  CAS  Google Scholar 

  44. A Goy A Younes P McLaughlin et al. (2005) ArticleTitlePhase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 23 667–675 Occurrence Handle15613697 Occurrence Handle10.1200/JCO.2005.03.108 Occurrence Handle1:CAS:528:DC%2BD2MXitVKisL0%3D

    Article  PubMed  CAS  Google Scholar 

  45. OA O'Connor J Wright C Moskowitz et al. (2005) ArticleTitlePhase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma J Clin Oncol 23 676–684 Occurrence Handle15613699 Occurrence Handle10.1200/JCO.2005.02.050 Occurrence Handle1:CAS:528:DC%2BD2MXitVKisLg%3D

    Article  PubMed  CAS  Google Scholar 

  46. SJ Strauss L Maharaj S Hoare et al. (2006) ArticleTitleBortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity J Clin Oncol 24 2105–2012 Occurrence Handle16606971 Occurrence Handle10.1200/JCO.2005.04.6789 Occurrence Handle1:CAS:528:DC%2BD28Xlt1amu70%3D

    Article  PubMed  CAS  Google Scholar 

  47. A Belch CT Kouroukis M Crump et al. (2007) ArticleTitleA phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150 Ann Oncol 18 116–121 Occurrence Handle16971665 Occurrence Handle10.1093/annonc/mdl316 Occurrence Handle1:STN:280:DC%2BD2s%2FisVWgtA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  48. RI Fisher SH Bernstein BS Kahl et al. (2006) ArticleTitleMulticenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma J Clin Oncol 24 4867–4874 Occurrence Handle17001068 Occurrence Handle10.1200/JCO.2006.07.9665

    Article  PubMed  Google Scholar 

  49. BD Cheson SJ Horning B Coiffier et al. (1999) ArticleTitleReport of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1244–1253 Occurrence Handle10561185 Occurrence Handle1:STN:280:DC%2BD3c%2FivF2itg%3D%3D

    PubMed  CAS  Google Scholar 

  50. de Vos S, Dakhil S, McLaughlin P, et al. (2005) Bortezomib plus rituximab in patients with indolent non-Hodgkin's lymphoma (NHL): a phase 2 study. Blood (ASH Annual Meeting Abstracts) 106: no. 17

  51. B Coiffier E Lepage J Briere et al. (2002) ArticleTitleCHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235–242 Occurrence Handle11807147 Occurrence Handle10.1056/NEJMoa011795 Occurrence Handle1:CAS:528:DC%2BD38XmslGgsw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  52. P Feugier A Van Hoof C Sebban et al. (2005) ArticleTitleLong-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 4117–4126 Occurrence Handle15867204 Occurrence Handle10.1200/JCO.2005.09.131 Occurrence Handle1:CAS:528:DC%2BD2MXmt1elsr0%3D

    Article  PubMed  CAS  Google Scholar 

  53. TM Habermann EA Weller VA Morrison et al. (2006) ArticleTitleRituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 3121–3127 Occurrence Handle16754935 Occurrence Handle10.1200/JCO.2005.05.1003 Occurrence Handle1:CAS:528:DC%2BD28XnslKhsL4%3D

    Article  PubMed  CAS  Google Scholar 

  54. M Pfreundschuh L Trumper A Osterborg et al. (2006) ArticleTitleCHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 379–391 Occurrence Handle16648042 Occurrence Handle10.1016/S1470-2045(06)70664-7 Occurrence Handle1:CAS:528:DC%2BD28XjvFWlsbw%3D

    Article  PubMed  CAS  Google Scholar 

  55. Leonard JP, Furman RR, Cheung YK, et al. (2007) CHOP-R + bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL). Proc Am Soc Clin Oncol 25: no. 8031

    Google Scholar 

  56. Mounier N, Ribrag V, Haioun C, et al. (2007) Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: a randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Proc Am Soc Clin Oncol 25: no. 8010

    Google Scholar 

  57. Zinzani PL, Tani M, Musuraca G, et al. (2006) Phase II study of proteasome inhibitor bortezomib (Velcade®) in patients with relapsed/refractory T-cell lymphoma: preliminary results. Blood (ASH Annual Meeting Abstracts) 108: no. 2462

  58. C Tan TA Waldmann (2002) ArticleTitleProteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia Cancer Res 62 1083–1086 Occurrence Handle11861386 Occurrence Handle1:CAS:528:DC%2BD38XitVSmsbk%3D

    PubMed  CAS  Google Scholar 

  59. Y Satou K Nosaka Y Koya et al. (2004) ArticleTitleProteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro Leukemia 18 1357–1363 Occurrence Handle15190257 Occurrence Handle10.1038/sj.leu.2403400 Occurrence Handle1:CAS:528:DC%2BD2cXlvVehsrw%3D

    Article  PubMed  CAS  Google Scholar 

  60. VS Rajkumar PG Richardson T Hideshima et al. (2005) ArticleTitleProteasome inhibition as a novel therapeutic target in human cancer J Clin Oncol 23 630–639 Occurrence Handle15659509 Occurrence Handle10.1200/JCO.2005.11.030 Occurrence Handle1:CAS:528:DC%2BD2MXitVartb0%3D

    Article  PubMed  CAS  Google Scholar 

  61. JR Berenson HH Yang K Sadler et al. (2006) ArticleTitlePhase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma J Clin Oncol 24 937–944 Occurrence Handle16418495 Occurrence Handle10.1200/JCO.2005.03.2383 Occurrence Handle1:CAS:528:DC%2BD28Xitl2qt70%3D

    Article  PubMed  CAS  Google Scholar 

  62. M Kropff G Bisping E Schuck et al. (2007) ArticleTitleBortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma Br J Haematol 138 330–337 Occurrence Handle17614819 Occurrence Handle10.1111/j.1365-2141.2007.06656.x Occurrence Handle1:CAS:528:DC%2BD2sXpsVClt7g%3D

    Article  PubMed  CAS  Google Scholar 

  63. A Suvannasankha GG Smith BE Juliar et al. (2006) ArticleTitleWeekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma Clin Lymphoma Myeloma 7 131–134 Occurrence Handle17026824 Occurrence Handle1:CAS:528:DC%2BD28XhtFGhtLfO Occurrence Handle10.3816/CLM.2006.n.050

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kensei Tobinai.

About this article

Cite this article

Tobinai, K. Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int J Clin Oncol 12, 318–326 (2007). https://doi.org/10.1007/s10147-007-0695-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-007-0695-5

Key words

Navigation